@article{7609a5d3d1b8447b8f73f39fa07abbc3,
title = "Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan",
abstract = "Background/purpose: Chronic hepatitis C virus (HCV) infection is a major cause of morbidity and mortality in patients with hemophilia. However, the efficacy and safety of pegylated interferon (PEG-IFN) plus ribavirin (RBV) for hemophilic patients with chronic HCV infection in Taiwan are still unknown. The aim of this study is to report the efficacy and safety of PEG-IFN plus RBV in a single center in Taiwan. Methods: In an open-label single-treatment one-arm cohort study, 12 hemophilic patients with elevated alanine aminotransferase level more than two times the upper limit of normal for more than 3 months received 180μg/week of PEG-IFN-α-2a plus RBV 1000-1200mg/day at a cut-off value of 75kg. The duration of treatment was 48 weeks for patients with HCV Genotype 1/4 infection and 24 weeks for patients with HCV Genotype 2/3 infection. Efficacy of therapy was expressed as sustained virological response (SVR). Results: Eight patients achieved SVR (66.7%). The SVR rates were 57%, 100%, 100%, and 0% for patients with HCV Genotypes 1, 2, 3, and 4 infection, respectively. Adverse events (AEs) developed in 10 patients (83.3%). Severe thrombocytopenia developed in one patient. However, the patient did not suffer from severe bleeding. Conclusion: Our study shows that the SVR rates are similar in hemophilic and nonhemophilic patients with chronic HCV infection who receive PEG-IFN-α-2a plus RBV in Taiwan. The rate of AEs also resembled other studies in nonhemophilic patients in Taiwan. No patient suffered from severe bleeding. However, large-scale, well-conducted studies are still needed to verify the treatment efficacy and safety. {\textcopyright} 2013.",
keywords = "Hemophilia, Hepatitis C, Pegylated interferon, Ribavirin, Viral response, alanine aminotransferase, bilirubin, creatinine, peginterferon alpha2a, ribavirin, serum albumin, alpha interferon, antivirus agent, macrogol derivative, recombinant protein, adult, alanine aminotransferase blood level, anemia, Article, bleeding, chronic hepatitis, clinical article, clinical trial, cohort analysis, coughing, decompensated liver cirrhosis, drug dose reduction, drug efficacy, drug induced headache, drug safety, drug withdrawal, fatigue, female, flu like syndrome, follow up, hemophilia, hepatitis C, Hepatitis C virus genotype 1, Hepatitis C virus genotype 2, Hepatitis C virus genotype 3, Hepatitis C virus genotype 4, human, human tissue, insomnia, liver cell carcinoma, lung tuberculosis, major depression, male, middle aged, myalgia, neutropenia, prospective study, pruritus, sepsis, sustained virological response, Taiwan, thrombocytopenia, treatment duration, treatment response, blood, complication, drug combination, drug effects, genetics, genotype, hemophilia A, Hepacivirus, Hepatitis C, Chronic, procedures, treatment outcome, virology, virus load, Adult, Alanine Transaminase, Antiviral Agents, Cohort Studies, Drug Therapy, Combination, Genotype, Hemophilia A, Humans, Interferon-alpha, Male, Middle Aged, Polyethylene Glycols, Recombinant Proteins, Treatment Outcome, Viral Load",
author = "Jung-An Lin and Yeu-Chin Chen and Shin-Nan Cheng and Peng-Jen Chen and Heng-Cheng Chu and Tsai-Yuan Hsieh and Yu-Lueng Shih",
note = "被引用次數：3 Export Date: 22 March 2016 CODEN: JFASE 通訊地址: Shih, Y.-L.; Division of Gastroenterology, Tri-Service General Hospital, Number 325, Section 2, Chenggong Road, Taiwan 化學物質/CAS: alanine aminotransferase, 9000-86-6, 9014-30-6; bilirubin, 18422-02-1, 635-65-4; creatinine, 19230-81-0, 60-27-5; peginterferon alpha2a, 198153-51-4; ribavirin, 36791-04-5; serum albumin, 9048-46-8; Alanine Transaminase; Antiviral Agents; Interferon-alpha; peginterferon alfa-2a; Polyethylene Glycols; Recombinant Proteins; Ribavirin 商標： pegasys, Hoffmann La Roche, Switzerland; rebetol, Schering, United States 參考文獻: Yee, T., Griffioen, A., Sabin, C.A., Dusheiko, G., Lee, C., The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985 (2000) Gut, 47, pp. 845-851; Rumi, M.G., Colombo, M., Gringeri, A., Mannucci, P.M., High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels (1990) Ann Intern Med, 112, pp. 379-380; Chen, D.S., Kuo, G.C., Sung, J.L., Lai, M.Y., Sheu, J.C., Chen, P.J., Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience (1990) J Infect Dis, 162, pp. 817-822; Franchini, M., Hepatitis C in haemophiliacs (2004) Thromb Haemost, 92, pp. 1259-1268; Lee, C., Dusheiko, G., The natural history and antiviral treatment of hepatitis C in haemophilia (2002) Haemophilia, 8, pp. 322-329; Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Dusheiko, G.M., Lee, S.S., Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis (2000) N Engl J Med, 343, pp. 1673-1680; Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial (2001) Lancet, 358, pp. 958-965; Zeuzem, S., Feinman, S.V., Rasenack, J., Heathcote, E.J., Lai, M.Y., Gane, E., Peginterferon alfa-2a in patients with chronic hepatitis C (2000) N Engl J Med, 343, pp. 1666-1672; Franchini, M., Mengoli, C., Veneri, D., Mazzi, R., Lippi, G., Cruciani, M., Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis (2008) J Antimicrob Chemother, 61, pp. 1191-1200; Lee, S.D., Chan, C.Y., Wang, Y.J., Wu, J.C., Lai, K.H., Tsai, Y.T., Seroepidemiology of hepatitis C virus infection in Taiwan (1991) Hepatology, 13, pp. 830-833; Seeff, L.B., Hollinger, F.B., Alter, H.J., Wright, E.C., Cain, C.M., Buskell, Z.J., Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study (2001) Hepatology, 33, pp. 455-463; Zhang, M., Rosenberg, P.S., Brown, D.L., Preiss, L., Konkle, B.A., Eyster, M.E., Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia (2006) Blood, 107, pp. 892-897; Liu, C.J., Chuang, W.L., Lee, C.M., Yu, M.L., Lu, S.N., Wu, S.S., Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses (2009) Gastroenterology, 136, pp. 496-504. , e3; Liu, C.H., Liu, C.J., Lin, C.L., Liang, C.C., Hsu, S.J., Yang, S.S., Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial (2008) Clin Infect Dis, 47, pp. 1260-1269; Yu, M.L., Dai, C.Y., Huang, J.F., Chiu, C.F., Yang, Y.H., Hou, N.J., Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial (2008) Hepatology, 47, pp. 1884-1893; Yu, M.L., Dai, C.Y., Lin, Z.Y., Lee, L.P., Hou, N.J., Hsieh, M.Y., A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan (2006) Liver Int, 26, pp. 73-81; Chuang, W.L., Yu, M.L., Dai, C.Y., Chang, W.Y., Treatment of chronic hepatitis C in southern Taiwan (2006) Intervirology, 49, pp. 99-106; Yu, M.L., Dai, C.Y., Huang, J.F., Hou, N.J., Lee, L.P., Hsieh, M.Y., A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C (2007) Gut, 56, pp. 553-559; Yu, M.L., Chuang, W.L., Treatment of chronic hepatitis C in Asia: when East meets West (2009) J Gastroenterol Hepatol, 24, pp. 336-345; Huang, C.F., Huang, J.F., Yang, J.F., Hsieh, M.Y., Lin, Z.Y., Chen, S.C., Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin (2012) J Hepatol, 56, pp. 34-40; Liu, C.H., Liang, C.C., Liu, C.J., Tseng, T.C., Lin, C.L., Yang, S.S., Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy (2012) Antivir Ther, 17, pp. 477-484; Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance (2009) Nature, 461, pp. 399-401; Witkos, M., Yi, Q.L., Heathcote, J., Kapral, M.K., Krahn, M.D., Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients (2006) Can J Gastroenterol, 20, pp. 107-111; Posthouwer, D., Plug, I., van der Bom, J.G., Fischer, K., Rosendaal, F.R., Mauser-Bunschoten, E.P., Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment (2005) Haemophilia, 11, pp. 270-275; Kevans, D., Farrell, G., Hopkins, S., Mahmud, N., White, B., Norris, S., Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes (2007) Haemophilia, 13, pp. 593-598; Pockros, P.J., Shiffman, M.L., Schiff, E.R., Sulkowski, M.S., Younossi, Z., Dieterich, D.T., Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy (2004) Hepatology, 40, pp. 1450-1458; Koirala, J., Gandotra, S.D., Rao, S., Sangwan, G., Mushtaq, A., Htwe, T.H., Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy (2007) J Viral Hepat, 14, pp. 782-787; Collantes, R.S., Younossi, Z.M., The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin (2005) J Clin Gastroenterol, 39, pp. S9-S13; Shiffman, M.L., Salvatore, J., Hubbard, S., Price, A., Sterling, R.K., Stravitz, R.T., Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha (2007) Hepatology, 46, pp. 371-379; Afdhal, N.H., Dieterich, D.T., Pockros, P.J., Schiff, E.R., Shiffman, M.L., Sulkowski, M.S., Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study (2004) Gastroenterology, 126, pp. 1302-1311; Alavian, S.M., Tabatabaei, S.V., Keshvari, M., Behnava, B., Miri, S.M., Elizee, P.K., Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases (2010) Liver Int, 30, pp. 1173-1180; Yang, J.F., Kao, Y.H., Dai, C.Y., Huang, J.F., Hsieh, M.Y., Lin, Z.Y., Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan (2010) Hepatol Int, 4, pp. 732-740",
year = "2014",
doi = "10.1016/j.jfma.2013.10.010",
language = "English",
volume = "113",
pages = "727--733",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier B.V.",
number = "10",
}
